Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
214 participants
OBSERVATIONAL
2020-05-01
2022-02-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
We plan to evaluate over 1000 patients with positive COVID-19 results and their households.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A COVID-19 Symptom, Exposure and Immune Response Registry
NCT04348942
Evaluation of Immune Response in COVID-19 Patients
NCT04438629
Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19
NCT04373148
Precision Immunology to Determine the Immune Response in Patients With COVID-19
NCT04360733
Understanding Immunology and Patient Outcomes of COVID-19 in Hospitalized Patients
NCT04892797
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
With the extensive outbreak of COVID-19, a mass of studies with a large population have been reported. Wu et al. found that the mean R0 of COVID-19 was approximately 2.68(95% CI: 2.47-2.86) . The measures in which public health officials quarantine confirmed and isolate symptomatic cases in order to reduce the spread COVID-19 is the common practice used in most countries. However, a significant question remains in regards to the asymptomatically infected individuals, which may propagate the virus and impede infection control.
The problem To date, initial surveillance has focused primarily on patients with severe disease, and, as such, the full spectrum of the disease. The extent of asymptomatic disease is not clear. Mizumoto et al. mathematical model suggested 17.9-33.3% are asymptomatic carriers. The other question to consider is whether these asymptomatic carriers develop an immune response or continue viral shedding.
SARS-CoV-2, the causative viral agent of the disease COVID-19, is a coronavirus which bears the transmembrane glycoprotein spikes (S protein) typical of viruses in its clade. The spikes on SARS-CoV-2 allows the virus to enter host cells through the human receptor angiotensin converting enzyme 2 (ACE2), present in alveolar epithelial cells. These spikes are a prominent target of human immune responses and have been found to be highly immunogenic and induce antibody production. The receptor-binding domain (RBD) of the S protein is particularly targeted by neutralizing antibodies.
The diagnostic test in symptomatic patients is based on real time polymerase chain reaction (RT-PCR), which tests the existence of specific COVID-19 genes in the sample. However, there are growing numbers of reports of false negative results due to improper sample collection, low viral load or technical instability of the PCR.
Serology test aims to detect antibodies (immunoglobulin M - IgM, immunoglobulin G- IgG, immunoglobulin A - IgA) in the patient's' blood, i.e. the patient's immune response. The IgM antibodies usually show within 3-7 days from symptoms, whereas IgG antibodies follow within 10-14 days. Diseases which involve the respiratory tract usually cause elevation of IgA as well.
Zhao et al. have recently published data indicating that COVID-19 patients show typical antibody production times in response to acute viral infection with SARS-CoV-2. Overall, the data suggest that SARS-CoV-2 infection follows a seroconversion timeline similar to other viral infections. In their sample of 173 of hospitalized symptomatic confirmed patients, 93.1% (161/173) developed antibodies, where 82.7% developed IgM antibodies and 64.7% developed IgG antibodies. Importantly, all of these patients suffered from symptoms. The association between symptoms level, viral load and the immune response is yet to be determined.
Closed settings, such as households, have a defined population that may not mix readily with the larger surrounding community, and therefore such settings can provide a strategic way to track emerging respiratory infections and characterize virus transmission patterns because the denominator can be well defined. Also, exposure is within the setting, and follow-up of household contacts is generally more feasible in this well-defined setting as compared to an undefined one. Following close contacts with similar levels of exposure to infection from primary cases can also permit identification of the asymptomatic fraction.
Our solution The purpose of the current study is the evaluate the immune response, i.e developing anti-SARS-CoV-2 antibodies in the asymptomatic cases, in a household study design.
We plan to evaluate over 1000 patients with positive COVID-19 results and their households. The plan includes evaluation of their symptoms, viral load and immune response every 10 days in a period of 12 weeks. Next, Analysis of the cause of the immune response differences between subjects by sequencing their DNA and most importantly of the ACE2 gene - the receptor the virus attacks.
This will shed the needed light on the connection between symptoms, viral load and immune response. The association between viral load, symptoms and immune response will enable: monitor disease progress, predict patients who are at high risk to develop severe symptoms, determine immunity to the virus and most importantly locate the chronic carriers which do not develop immunity.
Protocol Following a positive COVID-19 RT-PCR result in the Shamir medical center lab, the subject will be contacted by telephone and will be offered to participate in the study. Upon consent, medical staff will arrive to the subject's house and further explain the details of the study and ask for an informed consent of the subject and any of the households over 18 years old. Upon signing an informed consent, each of the subject will fill a symptoms report and provide an oropharyngeal swab and blood sample (10-20cc).
Every 10 days within 12 weeks, a researcher will visit the subjects house, and repeat the procedure (symptoms questionnaire, blood withdrawal and oropharyngeal swab).
Following the last evaluation (12th week), every 4-8 weeks within 1 year, a researcher will visit the subjects hosue and perform filling of symptoms questionnaire and blood withdrawal.
Serology kits:
1. LIAISION SARS-CoV-2 IgM (Diasorin, Saluggia, Italy)
2. LIAISION SARS-CoV-2 S1/S2 IgG (Diasorin, Saluggia, Italy)
3. ARCHITECT SARS-CoV-2 N IgG Immunoassay (Abbot, Illinois, U.S.A)
Rt-PCR kit RT-PCR will be performed using 3 primers and 3 probes in addition to one human RNase primer and probe.
Procedure
1. Arrival to the subjects house
2. Medical staff will use appropriate protective medical gear.
3. Blood withdrawal for 3 blood tubes (15-20cc)
4. Oropharyngeal swab
5. Samples will be kept at 2-8c degrees.
6. Samples will be returned to Shamir Medical Center lab in 2-8c degrees.
7. RT-PCR will be performed.
8. Serology will be performed using the available kits. Each subject will be sampled 9 times (every 10 days within 12 weeks in addition to the first contact). Blood samples will be kept and stored at -80°C for future research purposes.
Long term evaluation will include Blood sample and questionnaires every 4-8 weeks for 1 year from the final evaluation (12th week).
Timing
1. The first evaluation will be completed for both the patient and his/her households within 1-7 days of receiving the RT-PCR positive result
2. Following the first evaluation, each participant will be evaluated every 10 days (±2 days) for 100 days. In total 10 additional times.
In summary, each participant will be evaluated 11 times (first evaluation + 10 additional evaluations).
3. Following the last evaluation, each participant will be evaluated every 4-8 weeks for 1 year. In total 6-12 times.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Symptomatic
COVID-19 RT-PCR positive patients with reported symptoms
COVID-19 RT-PCR
Nasoropharyngeal swabs for COVID-19 RT-PCR - initial screening/retest +every 10 days in 100 days followup period
COVID-19 Serology
Blood samples for COVID-19 serology - initial screening/retest +every 10 days in 100 days followup period Each sample will be examined by 4-6 serology kits.
Symptoms questionnare
Symptoms questionnaire which will be filled by participant on initial screening/retest visit + every 10 days in 100 days followup period
Asymptomatic
COVID-19 RT-PCR positive patients without presenting any symptoms
COVID-19 RT-PCR
Nasoropharyngeal swabs for COVID-19 RT-PCR - initial screening/retest +every 10 days in 100 days followup period
COVID-19 Serology
Blood samples for COVID-19 serology - initial screening/retest +every 10 days in 100 days followup period Each sample will be examined by 4-6 serology kits.
Symptoms questionnare
Symptoms questionnaire which will be filled by participant on initial screening/retest visit + every 10 days in 100 days followup period
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
COVID-19 RT-PCR
Nasoropharyngeal swabs for COVID-19 RT-PCR - initial screening/retest +every 10 days in 100 days followup period
COVID-19 Serology
Blood samples for COVID-19 serology - initial screening/retest +every 10 days in 100 days followup period Each sample will be examined by 4-6 serology kits.
Symptoms questionnare
Symptoms questionnaire which will be filled by participant on initial screening/retest visit + every 10 days in 100 days followup period
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Over 18 years old
* Ability to sign an informed consent
Exclusion Criteria
* Pregnancy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assaf-Harofeh Medical Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Shay Efrati
Head of Research and Development Unit, Shamir Medical Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shai Efrati, MD
Role: PRINCIPAL_INVESTIGATOR
Head of Research and Development Unit
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assaf-Harofeh Medical Center
Ramla, , Israel
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020 Feb 29;395(10225):689-697. doi: 10.1016/S0140-6736(20)30260-9. Epub 2020 Jan 31.
Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, Wang M. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA. 2020 Apr 14;323(14):1406-1407. doi: 10.1001/jama.2020.2565.
Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020 Mar;25(10):2000180. doi: 10.2807/1560-7917.ES.2020.25.10.2000180.
Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li J, Qian S, Hong C, Wang F, Liu Y, Wang Z, He Q, Li Z, He B, Zhang T, Fu Y, Ge S, Liu L, Zhang J, Xia N, Zhang Z. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020 Nov 19;71(16):2027-2034. doi: 10.1093/cid/ciaa344.
Related Links
Access external resources that provide additional context or updates about the study.
WHO COVID-19 situation reports
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
105-20-ASF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.